Abstract:To investigate response and survival of radiotherapy (RT) for hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava, and to analyze prognostic factors. From January 2010 to December 2016, a total of 61 cases of hepatocellular carcinoma with pathological or clinical diagnosis of hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava were enrolled this study. Main portal vein tumor thrombosis (PVTT) was defined as tumor thrombi was located in main trunk or first branches of portal vein. Fifty-five patients were with PVTT and 4 patients were with venous vein tumor thrombosis alone, respectively. In addition, another 2 patients were with both vein thromboses. All patients had a liver function of Child-Pugh A before radiotherapy. Eighty-five percent of patients (52/61) had a history of hepatitis B, 2% (2/61) had hepatitis C, and 12% (7/61) had no history of hepatitis. Eighty-four percent of patients (51/61) had previously received transcatheter arterial chemoembolization (TACE). Eight patients were treated with concurrent RT and sorafenib. Tumor response was evaluated in one to three months after completion of RT. Survival and prognostic factors were analyzed by Kaplan-Meier method and Cox regression model. The factors included gender, age, history of hepatitis, AFP level before radiotherapy, number of intrahepatic lesions, maximum tumor diameter (MTD), combined TACE, radiotherapy dose were included in analysis of prognosis. All patients were treated with intensity modulated radiotherapy by conventional fraction of 2Gy/f. The median dose was 50Gy (28-66Gy). Response rate (RR, complete response + partial response) was 55.7% when considering all lesions of whole body. In field of RT, RR of the primary tumor was 77.1% and RR of the tumor thrombosis was 83.7%. The 2-year overall survival was 29.9% and median survival time (MST) was 13.6 months. Median time to progression (TTP) was 4.7 months. The 2-year progression free survival of tumor thrombosis was 88.6%. Multivariate analysis showed that the MTD>10cm was an independent poor prognostic factor of TTP (HR, 1.961, 95%CI, 1.034-3.717). TTP in patients with MTD≤10cm and MTD>10cm were 5.0 months and 3.3 months (p=0.026), respectively. However, for MST, combination of TACE (both before or after RT) was an independent favor prognostic factor (HR, 0.184, 95%CI, 0.06-0.565). MST of combination therapy was 15 months, and MST of patients receiving radiotherapy alone was 4 months (p<0.001). Of all patients, grade III or higher liver function damage was 1.6%, and no lethal radiation-induced liver disease occurred. Grade III or higher hematological toxicity was 11.5%. The tumor thrombosis is more sensitive to radiation therapy than the primary tumor. Radiotherapy improves survival by the perfect control of tumor thrombosis. Progression of outside field of RT is primary failure mode for patients with main PVTT. Combination of radiotherapy and TACE is benefit to survivals.

The Progress in Diagnosis and Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Treatment Options for Portal Hypertension in the Era of Liver Transplantation

[Progress in Surgical Treatment of Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].

Reply to ‘how to Select Eligible Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus for Deceased Donor Liver Transplantation?’

Efficacy of Different Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Efficacy And Prognosis Of Radiotherapy For Hepatocellular Carcinoma With Tumor Thrombosis In Main Portal Vein Or/And Vena Cava

Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy

Advances in Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Study of the changes of serum hyaluronic acid during porcine liver transplantation: influence of warm ischemia.

[Comparison of the Results and Therapies for Hepatocellular Carcinoma with Tumor Thrombosis in Portal Vein].

Comprehensive Management of Hepatocellular Carcinoma Complicated with Portal Vein or Bile Duct Tumor Thrombus

Hepatocellular Carcinoma Associated with Tumor Thrombosis in the Portal Vein: the Effects of Different Treatments.

Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy

Original research article Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey

[Hepatic Resection with Removal of Tumor Thrombi for Hepatocellular Carcinoma with Tumor Thrombi in Portal Vein and Curative Analysis].

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Influencing Factors for Prognosis of Patients with Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus after Surgical Treatment

Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus

Research progress on the formation mechanism of hepatocellular carcinoma with portal vein tumor thrombus